Skip to content

The influence of tacrolimus stable doses of genetic pharmcology study on Han ethnicityin China in renal transplant patients

The influence of tacrolimus stable doses of genetic pharmcology study on Han ethnicityin China in renal transplant patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RNC-12002894
Enrollment
Unknown
Registered
2012-12-26
Start date
2012-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal transplant

Interventions

Case series:Nil

Sponsors

Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients for renal insufficiency for renal transplant patients; 2. age eighteen years old; 3. the first line allograft renal transplantation; 4. postoperative time in more than half a year, all taking with tacrolimus based immune inhibitors; 5. postoperative recovery the graft function smoothly; 6. patients on a voluntary basis to participate in this study and sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Renal transplantation received other drug clinical study of patients; 2. retransplantation or accept any other organ transplant patients; 3. serious with disease, such as cancer, systemic lupus erythematosus ; 4. the doses for some reason cannot achieve the stable dose; 5. study period there are serious heart, lung disease; 6. renal transplantation severe anemia.

Design outcomes

Primary

MeasureTime frame
blood concentration of tacrolimus;

Contacts

Public ContactWei Zhang
yjsd2003@163.com+86 0731-84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026